Research analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a report released on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
NASDAQ EVOK opened at $2.18 on Tuesday. The stock has a 50-day simple moving average of $2.81 and a two-hundred day simple moving average of $3.84. The firm has a market capitalization of $7.29 million, a P/E ratio of -0.76 and a beta of 0.59. Evoke Pharma has a fifty-two week low of $2.03 and a fifty-two week high of $17.40. The company has a debt-to-equity ratio of 0.70, a quick ratio of 10.45 and a current ratio of 10.65.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.71) earnings per share for the quarter. The company had revenue of $0.46 million for the quarter. Evoke Pharma had a negative net margin of 372.04% and a negative return on equity of 185.09%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.